Bioverativ Inc. Common Stock
BIVV
BIVV was delisted on the 8th of March, 2018.
467 hedge funds and large institutions have $5.28B invested in Bioverativ Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 467 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
52% more call options, than puts
Call options by funds: $21.4M | Put options by funds: $14.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$433M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$429M |
| 3 |
VH
ValueAct Holdings
San Francisco,
California
|
+$418M |
| 4 |
Primecap Management
Pasadena,
California
|
+$381M |
| 5 |
HM
HealthCor Management
New York
|
+$246M |
Top Sellers
BIVV Hedge Fund Activity: Q1 2017 in Review
467 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Bioverativ Inc. Common Stock (BIVV) for Q1 2017, worth a combined $5.28B.
Buyers outnumbered sellers: 467 funds opened new BIVV positions and 0 closed out — a net gain of 467 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $433M.
- 467 institutional investors held Bioverativ Inc. Common Stock (BIVV) as of Q1 2017, up from 0 in Q4 2016.
- Funds reported $5.28B of Bioverativ Inc. Common Stock stock for Q1 2017.
- 467 funds opened new Bioverativ Inc. Common Stock positions in Q1 2017 and 0 closed out, a net change of +467 holders.
- The largest Bioverativ Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $433M added.
Based on aggregated 13F filings for Q1 2017.